| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Heilongjiang ZBD Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.53 |
| 52 Week High | CN¥16.20 |
| 52 Week Low | CN¥8.89 |
| Beta | 0.33 |
| 11 Month Change | -15.22% |
| 3 Month Change | 0.29% |
| 1 Year Change | -29.61% |
| 33 Year Change | -36.41% |
| 5 Year Change | -19.37% |
| Change since IPO | -60.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603567 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -7.1% | -3.7% | -2.2% |
| 1Y | -29.6% | -17.3% | -17.9% |
Return vs Industry: 603567 underperformed the CN Pharmaceuticals industry which returned -17.3% over the past year.
Return vs Market: 603567 underperformed the CN Market which returned -17.9% over the past year.
Price Volatility
| 603567 volatility | |
|---|---|
| 603567 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 603567 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603567's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 2,545 | n/a | www.zbdzy.com |
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Heilongjiang ZBD Pharmaceutical Co., Ltd. Fundamentals Summary
| 603567 fundamental statistics | |
|---|---|
| Market cap | CN¥9.89b |
| Earnings (TTM) | CN¥511.96m |
| Revenue (TTM) | CN¥2.72b |
19.3x
P/E Ratio3.6x
P/S RatioIs 603567 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603567 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.72b |
| Cost of Revenue | CN¥1.45b |
| Gross Profit | CN¥1.27b |
| Other Expenses | CN¥757.56m |
| Earnings | CN¥511.96m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 46.62% |
| Net Profit Margin | 18.80% |
| Debt/Equity Ratio | 39.5% |
How did 603567 perform over the long term?
See historical performance and comparison